Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature

Kamleshun Ramphul1, Renuka Verma2, Nomesha Kumar3, Yogeshwaree Ramphul4, Stephanie Mejias5, Petras Lohana3

1Department of Pediatrics, Shanghai Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Department of Medicine, Guru Gobind Singh Medical College, Punjab, India; 3Department of Medicine, Liaquat University of Medicine and Health Sciences, Jamshoro, Pakistan; 4Department of Medicine, Sir Seewoosagur Ramgoolam National Hospital, Pamplemousses, Mauritius; 5Department of Family Medicine, The University Iberoamericana UNIBE School of Medicine, Santo Domingo, Dominican Republic

Abstract. As the world continues to struggle with the pandemic of COVID-19 (coronavirus disease 2019), several cases of mucormycosis have been reported in these patients with a high mortality rate. We conducted a review of literature and found 19 articles with 20 patients who developed mucormycosis during their COVID-19 infection. 14 (70%) were males, and 6 (30%) were females. While their mean age was 52.2 ± 17.3 years, affected men were older than females. Ten (50%) patients also had diabetes. Common clinical findings included ophthalmologic complaints, fever, shortness of breath, and facial pain. Amphotericin B was the most common antifungal used and around 40% of cases needed surgical management of the infection. Steroid use was reported in around 12 cases (60%). Unfortunately, the mortality rate was 65% in this group of patients. Several changes in care should be brought for a consistent prevention, early diagnosis, and strong management of mucormycosis in COVID-19 patients.

Key words: Mucormycosis, COVID-19, Fungal infection, Amphotericin B.

In late 2019, a new virus was identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) after several patients in Wuhan, China were hospitalized with atypical symptoms resembling pneumonia. The disease was eventually called COVID-19 (coronavirus disease 2019) (1, 2). The virus became a pandemic as more than 206 million people have been tested positive, and 4.3 million lost their lives globally (3). COVID-19 can present with a range of symptoms and has multiple risk factors influencing the outcome (4-7).

Fungal infections are typically considered as opportunistic infections, meaning they thrive when the host immune system is compromised. Initially, at the start of the pandemic, many patients started showing signs and findings of pulmonary aspergillosis while admitted suffering from severe COVID-19 (8). However, in recent months, reports of mucormycosis infections involving COVID-19 patients have expanded fast across multiple countries (9). The management and treatment of mucormycosis can be expensive and challenging for several developing countries that are already struggling to control the spread of COVID-19. Mucormycosis was designated as an epidemic by the Rajasthan government in India on May 19, 2021, and numerous states are also seeing...
an increase in new cases and deaths connected to the fungus. (10, 11). Therefore, we conducted a review to, first, know the disease in general, and then further used published case reports from the literature to better understand the symptoms, prognosis, management, and possible risk factors of this condition in patients with COVID-19.

What is Mucormycosis?

Mucormycosis, previously known as Zygomy- 
cosis, is a life-threatening infection caused by the 
filamentous fungi of the order of “Mucorales” (12). 
Multiple species that have been identified in humans, 
such as “Apophysomyces (A. variabilis), Cunninghama 
ella (C. berthelotiae), Lichtheimia (Absidia) (L. corymbifera 
L. raosa), Mucor (M. circinelloides), Rhizopus (R. arrhi 
zus (oryzae) R. microsporus), Rhizomucor (R. pusillus), 
and Saksenaea (S. vasiformis)” (13). Mucorales can be 
present in rotting materials such as fruits and 
vegetables, and in the soil. It is very resistant to high 
temperatures too. The Rhizopus species tend to be 
the most common one involving up to 70% of cases of 
mucormycosis in immunocompromised patients (13-
15). The Apophysomyces species was first identified in 
India in 1979 and is believed to prefer tropical and 
subtropical climates. Several developing countries in 
those climatic areas are, thus, potentially at risk of this 
infection (16).

There are several routes of infection. The spores can 
enter the nose and lungs when inhaled, can be present 
in the gastrointestinal tract if present in contaminated 
food, or can be present in wounds or skin breaks (17). 
Once the spores have made their entry into immuno- 
competent patients, they are eaten up by neutrophils 
that eventually break them down. Therefore, patients 
with low levels of neutrophils or with impaired func-
tion of neutrophils are at very high risk (13, 16). Some 
studies further pointed out that patients with AIDS 
did not have a higher risk of developing the infection, 
and this confirmed that neutrophils were the primary 
mechanism of host defense instead of T cells (15).

Mucormycosis has also been observed in several 
immuno-competent hosts such as trauma patients. 
Diabetics who have uncontrolled management of 
their blood sugar levels and previous history of dia-
abetic ketoacidosis (DKA) are also at a higher risk (14). 
Rhizopus arrhizus species contain ketone reductase, 
which enables the fungi to overcome the acidic envi-
ronment in DKA patients. The ability for the fungi 
to take up unbound iron from the host has also been 
linked with the pathogenesis (15, 18).

The presentation of the infection usually relies 
on the route of entry of the spores. Patients can have 
rhinocerebral mucormycosis with symptoms of “facial 
umbness, ocular pain, and dysfunction, fever, as well 
as intranasal painless ulcersations with necrotic tissues”.
Pulmonary mucormycosis may lead to pneumonia and 
include “fever, shortness of breath, and even hemopty-
sis”. The cutaneous form of this infection, which can 
occur from sites of injury, can start as cellulitis that 
evitably becomes necrotic. Ingestion of spores can 
lead to gastrointestinal symptoms, including nausea, 
vomiting, diarrhea. Severe cases can even include 
hematemesis and melena (13, 15).

Since routine blood work is not very helpful in 
diagnosing the infection, biopsy samples are usually 
taken. On histopathology, the fungi is identified as 
a “non-septated or minimally septated broad-based 
hyphae” (13). Management includes anti-fungal 
therapy via Amphotericin B, surgical debridement if 
needed, and symptomatic care and therapy. The pri-
mary cause of infection should also be addressed. Sev-
eral other anti-fungal therapies, such as Posaconazole 
or isavuconazole have also been considered in the past. 
However, mucormycosis can be very deadly and have a 
mortality rate that varies between 25-87% (13, 15, 17).

Method

We used the keywords “COVID-19”, “SARS-
CoV-2”, “Coronavirus”, “Mucor”, and “zygomycosis” to 
identify cases of mucormycosis in COVID-19 patients 
published in English, French, Chinese, and Spanish 
between 2019 and 10th May 2021 on PubMed. The 
age, gender, presence of risk factors such as hyper-
tension, diabetes, obesity, immunosuppression, and 
the treatment used for the fungal infection were all 
recorded. Manuscripts that were not accessible or that 
did not provide enough information for our review
were rejected. The authors performed their search as two teams, and each team eventually presented their findings and discussed the results to set up a final choice of cases.

**Results**

The initial search provided 34 results, and both teams read 33 of them. One of the manuscripts was inaccessible at that time. After filtering cases for individual patient-level-data, we found 19 articles (table 1) that involved 20 patients (19-37). Among the 20 patients, 14 (70%) were males, and 6 (30%) were females. The mean age of the patients was 52.2 ± 17.3, with ages ranging from 22-86 years. However, the mean age of the female patients was 38.0 ± 14.1 years, while the mean age for male patients was 57.3 ± 15.8 years. Geographically, six cases (30%) were from the USA, five (25%) from India, three (15%) from Iran, and one from Austria, Brazil, Frana, Italy, Mexico, and UK each. 10 (50%) patients had a history of diabetes and 7 (35%) had hypertension. Other comorbidities that were present included end-stage renal disease/chronic kidney disease (3 patients, 15%), obesity (3 patients, 15%), asthma (2 patients, 10%), and immunosuppressed states/malignancy (three patients; one for Acute myelogenous leukemia, follicular lymphoma and heart transplant each).

The time of diagnosis of mucormycosis varied drastically for the patients between on admission to even three months after hospitalization for COVID-19, while one patient was even diagnosed during his post-mortem analysis (35). The common findings involved ophthalmologic complaints, fever, shortness of breath, and facial pain. One patient with Gastrointestinal mucormycosis also had abdominal pain, anemia and melena (22). 16 (80%) patients used non-invasive Oxygen supply, and eventually, a total of 11 (55%) patients were intubated for mechanical ventilation. The fungi affected multiple systems. Ten patients (50%) had rhino/sino/paranasal/orbital mucormycosis, while mycotic mycosis and gastrointestinal mucormycosis were reported in one patient each. Six patients (30%) had pulmonary mucormycosis, amongst which one also had aspergillosis. Mixed infection due to both aspergillus and Rhizopus was found in one patient (5%) (26). Hanley et al. even reported a case of disseminated mucormycosis that reached the patient’s lungs, hilar lymph nodes, kidneys, and brain (summarized in table 1) (36).

Several different approaches were used for the management of the fungal infection. Amphotericin B was the most common drug used, while other drugs such as Voriconazole, Posaconazole, Isavuconazole, Caspofungin, itraconazole were also being considered. Around 40% of cases also needed surgical debridement of the infection. Steroid use was reported in about 60% of cases, and may have been higher if unrecorded in the case reports but given during their hospitalization or during early management of COVID-19. Unfortunately, 13 patients (65%) died, while 7 patients (35%) survived. The mean ages of the deceased and survival cases were 51.8 ± 18.2 years and 53.2 ± 16.8 years each.

**Discussion**

Several developing countries are struggling to contain the spread of COVID-19 (11), and the high mortality rates and rising numbers of mucormycosis infections are crippling their health care system (38, 39), as well as their economic balance. Our analysis provides several vital points that should raise further questions on the screening, planning, and management of such patients.

While mucormycosis is typically known to infect diabetic patients (15), 50% of cases reported in literature for COVID-19 patients were non-diabetics. Therefore, further research should be undertaken to determine whether hyperglycemia occurred during the hospitalization of non-diabetic patients as a result of their steroid use for the management of COVID-19 symptoms or as a result of the stress of their severe disease. (40). Physicians should also be encouraged to have regular random blood glucose checks for these non-diabetic patients along their diabetic cases of COVID-19. More males were affected than females in our study. Previously, while some studies have reported a balanced distribution of cases between the two sexes in non-COVID-19 patients (41), Mignogna et al. found a higher male to female ratio (42). A larger
Table 1. Cases of mucormycosis among COVID-19 patients in literature

| Author                  | Age (years) | Sex | Diabetes | Died | Treatment used for mucormycosis | Non-invasive O2 | Intubated or on ventilator | Other major co morbidities | Symptoms                                                                 | System/organ affected by mucor |
|-------------------------|-------------|-----|----------|------|---------------------------------|-----------------|--------------------------|---------------------------|--------------------------------------------------------------------------|--------------------------------|
| Mehta S et al. (19)     | 61          | M   | Yes      | Yes  | N/A                             | No              | Yes                      | N/A                       | “Fever before admission, afebrile on the day of admission, Shortness of breath, Orbital Cellulitis, Conjunctivitis, Keratitis Periorbital Edema” | Rhino Orbital Mucormycosis |
| Werthman-Ehrenreich A. et al. (20) | 33          | F   | Yes      | Yes  | Amphotericin B, Surgical debridement | Yes             | No                       | N/A                       | “Shortness of Breath, Altered mental status, Fixed Dilated Pupil with Complete Ophthalmoplegia” | Rhino Orbital Mucormycosis |
| Pasero D et al. (21)    | 66          | M   | No       | Yes  | Liposomal Amphotericin B, Itraconazole, Surgery | Yes             | Yes                      | Asthma, hypertension       | “COVID symptoms”                                                       | Gastrointestinal Mucormycosis |
| Monte Junior ESD et al. (22) | 86          | M   | No       | Yes  | N/A                             | Yes             | Yes                      | Hypertension               | “COVID symptoms, fever, shortness of breath, Acute Diarrhea, Melena, Profound Anemia, Abdominal Pain” | Pulmonary Mucormycosis |
| Mekonnen ZK et al. (23) | 60          | M   | Yes      | Yes  | Liposomal Amphotericin B, Caspofungin, Surgery, Posaconazole | Yes             | Yes                      | Asthma, Hyperlipidemia, Hypertension | “Shortness of breath, Fixed Pupil, Conjunctival Chemosis, Edema of Eyelids, Proptosis” | Rhino Orbital Mucormycosis |
| Garg D et al. (24)      | 55          | M   | Yes      | No   | Liposomal Amphotericin B, Itraconazole, Posaconazole | Yes             | No                       | Ischemic Cardiomyopathy, End-Stage Renal Disease on Dialysis, Hypertension | “Fewer, Shortness of breath, Cough with Expectoration” | Pulmonary Mucormycosis |
| Placik DA et al. (25)   | 49          | M   | No       | Yes  | Amphotericin B                  | Yes             | Yes                      | Bronchopulmonary Fistula, pneumothorax developed During Hospitalization | “Fever, Cough, Dyspnea” | Pulmonary Mucormycosis |
| Bellanger AP et al. (26) | 55          | M/A | Yes      | N/A  | Liposomal Amphotericin B        | Yes             | Yes                      | Follicular Lymphoma        | “Fever, Dyspnea”                                                        | Mixed Mold Infection due to Aspergillus and Rhizopus |
| Maini A et al. (27)     | 38          | M   | No       | No   | Amphotericin B, Surgery, Tobramycin, Nepalact | Yes             | No                       | N/A                       | “Fever, Shortness of breath, Body ache, u Swelling and Pain in Left Eye” | Sino Orbital Mucormycosis |

(Continued)
| Author                  | Age (years) | Sex | Diabetes | Died | Treatment used for mucormycosis | Non-invasive O2 | Intubated or on ventilator | Other major co morbidities | Symptoms                                                                 | System/organ affected by mucor |
|-------------------------|-------------|-----|----------|------|---------------------------------|----------------|---------------------------|---------------------------|--------------------------------------------------------------------------|---------------------------------|
| Khatri A et al.(28)     | 68          | M   | Yes      | Yes  | Liposomal Amphotericin B, Posaconazole, debridement | Yes            | Yes                       | Heart Transplant, Chronic Kidney Disease, Obstructive Sleep Apnea, Hypertension | “Nonproductive Cough, Fever, Non-Bloody Diarrhea, Sternal Wound Discharge” | Myotic Aneurysm                |
| Saldanha M et al.(29)   | 32          | F   | Yes      | No   | Amphotericin B, Surgery         | No             | No                        | N/A                       | “Left Eye Ptosis and Facial Pain”                                       | Paranasal Mucormycosis          |
| Veisi A et al.(30)      | 40          | F   | Yes      | No   | Surgery, Amphotericin B         | Yes            | No                        | N/A                       | “Bilateral Visual Loss and Periorbital Pain”                             | Rhino Orbital Mucormycosis      |
| Veisi A et al.(30)      | 54          | M   | Yes      | No   | Amphotericin B, Surgery         | Yes            | No                        | N/A                       | “Left Orbital Pain, Periorbital Swelling and Vision Loss”                 | Rhino Orbital Mucormycosis      |
| Johnson AK et al. (31)  | 79          | M   | Yes      | No   | Voriconazole                    | Yes            | No                        | Hypertension              | “Fever, Dyspnea, COVID-symptoms”                                        | Pulmonary Mucormycosis And Aspergillosis |
| Karimi-galougahi M et al.(32) | 61     | F   | No       | No   | Anti-Fungal and Surgery         | No             | No                        | N/A                       | “Right Hemifacial Numbness, Decreased Visual Acuity, Chemosis”            | Rhino Orbital Mucormycosis      |
| Waizel Haiat S et al.(33)| 24         | F   | Yes      | Yes  | Imipenem, Linezolid, Amphotericin B | Yes            | Yes                       | Obesity                   | “Pain in Left Mid Face, Left Lid Swelling, And Maxillary Hypoesthesia”   | Rhino Orbital Mucormycosis      |
| Kanwar A et al.(34)     | 56          | M   | No       | Yes  | Isavuconazole, Posaconazole     | Yes            | Yes                       | End Stage Renal Disease    | “Fatigue, Dyspnea, Hemoptysis”                                          | Pulmonary Mucormycosis          |
| Zurl C et al.(35)       | 53          | M   | No       | Yes  | Voriconazole                    | Yes            | Yes                       | Acute Myelogenous Leukemia, Obesity, Depression                           | Pulmonary Mucormycosis          |
| Hanley B et al.(36)     | 22          | M   | N/A      | Yes  | Caspofungin, Linezolid, Meropenem And Tigecycline | Yes            | Yes                       | Obesity and Hypothyroidism                                             | “Multisystemic, COVID-related, difficulty breathing”                     | Disseminated                   |
| Revannavar SM et al.(37)| N/A         | F   | Yes      | No   | Amphotericin B                  | No             | No                        | N/A                       | “Fewer, Left Eye Ptosis and Facial Pain and Fever”                       | Rhino Orbital Mucormycosis      |

N/A= not available, M= male, F= female
sample size may help clarify this finding. A gap in age difference between males and females was also observed in our study, and since the male group had one outlier at 22 years of age, the gap may be more significant than reported. Older men and younger women were the prominent cases recorded.

Patients with immunosuppression, malignancy, chronic inflammatory states, on dialysis, chronic kidney disease/renal insufficiency, and obesity have all been linked with a more severe outcome for COVID-19, and they are also at a higher risk of developing fungal infections (43-46). Therefore, these groups should be appropriately sequestrated during their hospitalizations to reduce the risk of nosocomial infections and fungal infections from other patients. Since half of the cases had ophthalmologic complaints and involved the rhino/sino/paranasal/orbital area, several changes can be brought in the protocols of management of COVID-19 patients. A thorough examination on admission, as well as daily examinations should be performed. However, given the rising cases of COVID-19 and the decreasing physician-to-patient ratio in developing countries, the physicians should also educate the patients to report symptoms that could hint towards the infection and be shown how to check for any such infections.

Mucormycosis has a high mortality rate (47), and in our study only 35% of the patients survived. Since Amphotericin B was used in most patients, protocols should also include a close eye on the possible side effects and a regular check on the patient’s electrolytes. The causes of death of these patients were not properly described in the case reports, and it is, therefore, difficult to hypothesize if the drugs used for their management could have been a precipitating factor for their deaths. Amphotericin B can cause several electrolyte imbalances such as hypokalemia, which can eventually lead to Torsades de Pointes and other cardiac arrhythmias. Close cardiac monitoring for patients and reporting their results may help understand the impact in such cases (48).

Conclusion

In summary, our analysis shows that several areas may need extra caution by physicians treating COVID-19 patients that can help lower the incidence of mucormycosis and improve their survival rates. We strongly advise the following to be considered by the treating physicians and to be included in the protocols:

- Regular blood glucose monitoring in all COVID-19 patients, including non-diabetics. Special attention to those receiving steroids.
- Educating all COVID-19 patients, hospitalized or non-hospitalized, on simple ways to locate symptoms and findings of mucormycosis.
- Encouraging physicians to anticipate side effects of antifungal therapies and correct them in a timely manner, before the onset of additional symptoms.

With proper preventive measures, early diagnosis, and appropriate care, the world will eventually be able to handle the new complication of this pandemic.

Conflicts of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

References

1. Ramphul K, Mejias SG. Coronavirus Disease: A Review of a New Threat to Public Health. Cureus 2020; 12:e7276.
2. Ramphul K, Ramphul Y, Park Y, Lohana P, Kaur Dhillon B, Sombans S. A comprehensive review and update on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus disease 2019 (COVID-19): what do we know now in 2021? Arch Med Sci Atheroscler Dis 2021; 6:5-13.
3. WHO COVID-19 Dashboard, available online https://covid19.who.int/ (accessed on 13 May 2021)
4. Ramphul K, Lohana P, Ramphul Y, et al. Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19. Arch Med Sci Atheroscler Dis 2021; 6:30-39.
5. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-148.
6. Aggarwal G, Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. J Diabetes 2020; 12:851-855.
7. Cheruiyot I, Henry B, Lippi G, et al. Acute Kidney Injury is Associated with Worse Prognosis In COVID-19 Patients: A Systematic Review and Meta-analysis. Acta Biomed 2020; 91:e2020029.

8. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19-Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. Journal of Fungi 2020; 6:91.

9. What is the deadly ‘black fungus’ seen in Covid patients in India?, available online https://www.theguardian.com/global/2021/may/11/what-is-the-dangerous-black-fungus-being-seen-in-covid-patients-in-india-mucormycosis (accessed on 13 May 2021)

10. Verma R, Ramphul K, Kumar N, Lohana P. Investigating the impact of search results for fever, headache, cough, diarrhea, and nausea on the incidence of COVID-19 in India using Google Trends. Acta Biomed 2021; 92:e2021242.

11. Rajasthan declares black fungus an epidemic; cases pile up in several states | 10 points, available online https://www.indiatoday.in/coronavirus-outbreak/story/rajasthan-declares-black-fungus-an-epidemic-cases-pile-up-in-several-states-10-points-1804470-2021-05-19 (accessed on 20 May 2021)

12. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Jr., Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48:1743-1751.

13. Mucormycosis, available online https://www.statpearls.com/articlelibrary/viewarticle/25325/?utm_source=pubmed&utm_campaign=CME&utm_content=25325 (accessed on 19 May 2021)

14. Camara-Lemarroy CR, Gonzalez-Moreno EI, Rodríguez-Gutiérrez R, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014; 2014:562610.

15. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S16-22.

16. Chakrabarti A, Ghosh A, Prasad GS, et al. Apophysomyces elegans: an emerging zygomycete in India. J Clin Microbiol 2003; 41:783-788.

17. Reid G, Lynch JP, 3rd, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med 2020; 41:99-114.

18. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31:1109-1114.

19. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus 2020; 12:e10726.

20. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42:264.e265-264.e268.

21. Pasero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection 2020;1-6.

22. Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. Clin Endosc 2020; 53:746-749.

23. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plast Reconstr Surg 2021; 37:e40-e80.

24. Garg D, Muthu V, Sehgal IS, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia 2021; 186:289-298.

25. Plack DA, Taylor WL, Wink NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep 2020; 15:2378-2381.

26. Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. [published online ahead of print, 2021 Jan 27] Infect Dis Now 2021;S2666-9919(21)00030-0.

27. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep 2021; 82:105957.

28. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. J Mycol Med 2021; 31(2):101125.

29. Saldanha M, Reddy R, Vincent MJ. Title of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian J Otolaryngol Head Neck Surg 2021:1-4.

30. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2021:11206721211009450.

31. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021; 32:64-67.

32. Karimi-Galoughahi, M, Arastou, S, Haseli, S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021; 1-3.

33. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19. Cureus 2021; 13:e13163.

34. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A Fatal Case of Rhizopus aspergillus Pneumonia Following COVID-19. J Fungi (Basel) 2021; 7(3):174.

35. Zurc C, Hoenigl M, Schulz E, et al. Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy, J Fungi (Basel) 2021; 7(2):88.

36. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal
COVID-19: a post-mortem study. Lancet Microbe 2020; 1:e245-e253.

37. Revannavar SM, P SS, Samaga L, V KV. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021; 14:e241663.

38. Kowlessur S, Ori B, Zimmet P, Tuomilehto J, Chitson P, Ramphul Y. Tackling the COVID-19 pandemic in paradise: the Mauritian experience. The Lancet Diabetes & Endocrinology 2020; 8:878-879.

39. Ramphul K, Lohana P, Verma R, Sombans S. The impact of COVID-19 on cardiology departments. Arch Med Sci Atheroscler Dis 2021; 6:1-2.

40. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S16-22.

41. Egi M, Furushima N, Makino S, Mizobuchi S. Glycemic control in acute illness. Korean J Anesthesiol 2017; 70:591-595.

42. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Archives of internal medicine 1999; 159:1301-1309.

43. Mignogna MD, Fortuna G, Leuci S, et al. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis 2011; 15:e533-540.

44. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52:1193-1194.

45. Brar G, Pinheiro LC, Shusterman M, et al. COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. J Clin Oncol 2020; 38:3914-3924.

46. Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 2021; 18:298-307.

47. Hong HL, Lee YM, Kim T, et al. Risk factors for mortality in patients with invasive mucormycosis. Infect Chemother 2013; 45:292-298.

48. Usami E, Kimura M, Kanematsu T, et al. Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B. Exp Ther Med 2014; 7:941-946.

Correspondence:
Received: 1 May 2021
Accepted: 20 May 2021
Dr. Kamleshun Ramphul
Department of Pediatrics, Shanghai Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine; 1665 Kongjiang Road, Shanghai 200092, China
Telephone number: +86 21 6579 2951
https://orcid.org/0000-0001-9050-3581
E-mail: adramphul@hotmail.com